Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2021

Supporting Information

Generation of a quenched phosphonate activity-based probe for labelling the active KLK7 protease

Evangelos Bisyris,^a Eleni Zingkou,^a Golfo G. Kordopati,^a Minos Matsoukas,^a Plato A. Magriotis,^a Georgios Pampalakis^{*b} and Georgia Sotiropoulou^{*a}

^a Department of Pharmacy, School of Health Sciences, University of Patras, Rion Patras, 265 04, Greece
^b Department of Pharmacognosy-Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, 541 24, Greece

* Corresponding authors: gdsotiro@upatras.gr; gpampalakis@pharm.auth.gr

Contents

Chemical Synthesis	S2-S8
NMR, MS and HPLC raw data	S9-S35

Chemical Synthesis

Benzyl (1-(diphenoxyphosphoryl)-2-phenylethyl)carbamate

$Z-Phe^{P}-(OPh)_{2} (4)$



Benzyl carbamate **1** (3.02 g, 20 mmol, 1 eq.), 2phenylacetaldehyde **2** (2.33 ml, 20 mmol, 1 eq.), and triphenyl phosphite **3** (5.25 ml, 20 mmol, 1 eq.) were dissolved in DCM (40 ml) and Cu(OTf)₂ (0.722 g, 2 mmol, 0.1 eq.) was added. The mixture was stirred at room

temperature (rt) overnight until benzyl carbamate was consumed, as indicated by TLC. Then DCM was evaporated *in vacuo*, and MeOH was added. The resulting solution was kept at 4 °C until diphenyl phosphonate 4 was precipitated as a yellowish solid (5.5 g, yield 56%).

*R*_{*f*}: 0.58 (Hexane/EtOAc, 6:4)

¹**H-NMR** (600 MHz, CDCl₃), δ 7.33-7.13 (m, 18H), 7.08 (d, *J* = 7.9 Hz, 2H), 5.24 (d, *J* = 10.3 Hz, 1H), 5.03 (s, 2H), 4.90-4.77 (m, 1H), 3.44-3.39 (m, 1H), 3.07-3.01 (m, 1H).

³¹P-NMR (243 MHz, CDCl₃) δ 16.80 (major), 16.37 (minor).

ESI-MS: m/z calcd for $[M+Na]^+ C_{28}H_{26}NNaO_5P^+ 510.14$, found 510.27; calcd for $[M+K]^+ C_{28}H_{26}KNO_5P^+ 526.12$, found 526.22; calcd for $[2M+Na]^+ C_{56}H_{52}N_2NaO_{10}P_2^+$ 997.30, found 997.37.

Benzyl (1-(diethoxyphosphoryl)-2-phenylethyl)carbamate

$Z-Phe^{P}-(OEt)_{2}(5)$



The stirred solution of diphenyl phosphonate **4** (487 mg, 1 mmol, 1 eq), potassium fluoride dihydrate (940 mg, 10 mmol, 10 eq.), and a catalytic amount of 18-crown-6 ether (20 mg, 0.076 mmol, 0.076 eq) in EtOH (5 ml) was heated to reflux for 10 min and then left to cool at rt overnight. The solvent was

removed *in vacuo*, and water (20 ml) was added to the residue, followed by extraction with ethyl acetate (3 x 10 ml). The combined organic extracts were washed with 1 N NaOH (3 x 10 ml), water (10 ml), and brine (10 ml), dried over Na_2SO_4 , and concentrated *in vacuo* to afford the diethyl phosphonate **5** as a colorless oil (190 mg, yield 49%).

R_f : 0.18 (Hexane/EtOAc, 6:4).

¹**H NMR** (600 MHz, CDCl₃) δ 7.31-7.21 (m, 10H), 5.07 (d, *J* = 9.8 Hz, 1H), 4.99 (s, 2H), 4.42-4.36 (m, 1H), 4.13-3.99 (m, 4H), 3.25-3.21 (m, 1H), 2.88-2.82 (m, 1H), 1.29 (t, *J* = 7.0 Hz, 3H), 1.23 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (151 MHz, CDCl₃) δ 155.7, 136.6, 136.5, 136.3, 129.2, 128.4, 128.1, 127.9, 126.8, 66.9, 62.8, 62.7, 62.5, 62.5, 49.1, 48.1, 36.0, 16.4, 16.3.

³¹P NMR (243 MHz, CDCl₃) δ 23.94 (major), 23.32 (minor).

ESI-MS: m/z calcd for $[M+Na]^+ C_{20}H_{26}NNaO_5P^+$ 414.14, found 414.15; calcd for $[2M+Na]^+ C_{40}H_{52}N_2NaO_{10}P_2^+$ 805.30, found 805.13.

Benzyl (1-(chloro(ethoxy)phosphoryl)-2-phenylethyl)carbamate Z-Phe^p-(OEt)Cl (6)



To a stirred solution of diethyl phosphonate **5** (194 mg, 0.5 mmol, 1 eq.) in DCM, one drop of DMF was added. The solution cooled at 0 $^{\circ}$ C, and oxalyl chloride (0.127 ml, 1.5 mmol, 3 eq.) was added dropwise. The mixture was warmed at rt, and the

reaction was monitored by TLC. When **5** was consumed (16 h), the solvent was removed *in vacuo*, DCM was added ($2 \times 5 \text{ ml}$) and evaporated. The residue was used directly to the following reaction without further purification.

*R*_{*f*}: 0.26 (CHCl₃/MeOH, 9:1).

Tert-butyl 4-hydroxyphenethylcarbamate

Boc-NH-Tya-OH (8)



To a stirred solution of tyramine (7) (274 mg, 2 mmol, 1 eq.) in dioxane/water (1:1, 10 ml), sodium carbonate (212 mg, 2 mmol, 1 eq.) was added in one portion. The mixture was cooled at 0 °C, and di*tert*-butyl dicarbonate (Boc₂O) (0.5 ml, 2.2 mmol, 1.1 eq.) was added. One hour after the reaction mixture was left to warm at rt, ethyl acetate (20 ml) was added. The mixture was washed with 5% citric

acid (2 x 15 ml), water (15 ml), 5% NaHCO₃ (15 ml), and finally with brine (15 ml). The organic layer was dried over Na_2SO_4 , and after evaporation, the crude product was purified by column chromatography (silica gel, hexane/ethyl acetate 50% to 20%) to give the desired Boc-protected tyramine **8** as a colorless oil converted to white solid over several days (460 mg, yield 97%).

 R_f : 0.23 (Hexane/EtOAc, 6:4); 0.44 (CHCl₃/MeOH, 9:1). ¹H NMR (600 MHz, CDCl₃) δ 6.99 (d, J = 8.2 Hz, 2H), 6.79 (d, J = 8.4 Hz, 2H), 4.70 (s, 1H), 3.33-3.32 (m, 2H), 2.70-2.68 (m, 2H), 1.45 (s, 9H). ESI-MS: m/z calcd for [M+Na]⁺ C₁₃H₁₉NNaO₃⁺ 260.13, found 260.80.

Benzyl (1-((4-(2-*tert*-butyl carbonyl aminoethyl)phenoxy)(ethoxy)phosphoryl)-2-phenylethyl)carbamate

Z-Phe^P-(OEt)(OTya-Boc) (9)



To a stirred solution of chloride **6** (290 mg, 0.76 mmol, 1 eq.) in toluene (2 ml), Boc-NH-Tya-OH (**8**) (450 mg, 1.9 mmol, 2.5 eq.) and triethylamine (0.264 ml, 1.9 mmol, 2.5 eq.) were added. The mixture was stirred at rt overnight. Then diethyl ether (5 ml) was added and extracted with brine (10 ml). The organic layer was washed with 5% NaHCO₃ (4 x 5 ml), dried (Na₂SO₄), filtered through celite, and the solvents were evaporated. The crude product was

purified in column chromatography (silica gel, hexane/ethyl acetate 80% to 60%) to afford **9** as a white solid (50 mg, 11% after two steps).

 R_f : 0.33 (Hexane/EtOAc, 1:1).

¹**H NMR** (600 MHz, CDCl₃) δ 7.33-7.21 (m, 10H), 7.15-7.08 (m, 4H), 5.16 (t, *J* = 10.8 Hz, 1H), 5.03 & 4.99 (d, *J*_{AB} = 24.8 Hz, 2H), 4.20-4.13 (m, 2H), 3.35-3.29 (m, 3H), 2.97-2.95 (m, 1H), 2.77-2.50 (m, 2H), 1.45 (s, 9H), 1.29-1.19 (m, 3H).

¹³C NMR (151 MHz, CDCl₃) δ 155.8, 155.7, 136.2, 130.1, 129.9, 129.3, 128.5, 128.4, 128.4, 128.1, 128.0, 127.9, 127.8, 126.9, 120.6, 120.4, 67.1, 67.0, 63.7, 63.6, 63.5, 49.6, 48.5, 48.3, 41.7, 36.0, 35.4, 28.4, 16.7, 16.2.

³¹**P NMR** (243 MHz, CDCl₃) δ 20.84, 20.76.

ESI-MS: m/z calcd for $[M+Na]^+ C_{31}H_{39}N_2NaO_7P^+$ 605.24, found 605.30; calcd for $[M+K]^+ C_{31}H_{39}N_2KO_7P^+$ 621.21, found 621.23.

Tert-butyl 4-(((1-amino-2-

< phenylethyl)(ethoxy)phosphoryl)oxy)phenethylcarba-mate H₂N-Phe^P-(OEt)(OTya-Boc) (10)

To the stirred mixture of Z-Phe^P-(OEt)(OTya-Boc) (9) (50 mg, 86 μ mol, 1 eq.) and a catalytic amount of Pd (10% Pd-C, 10 mg, 20%



w/w) in MeOH (0.5 ml) triethylsilane (140 μ L, 860 μ mol, 10 eq.) was added dropwise under nitrogen atmosphere. When the reaction was complete, the mixture was filtered through celite, and solvents evaporated *in vacuo*. The resulting oil was used for the next step without further purification (42 mg crude).

*R*_{*f*}: 0.08 (Hexane/EtOAc, 6:4).

ESI-MS: m/z calcd for $[M+H]^+ C_{23}H_{34}N_2O_5P^+ 449.22$, found 449.48.

Tert-butyl 4-(((1-(2- benzyloxycarbonylamino-3-phenylpropanamido)-2-phenylethyl)(ethoxy)phosphoryl)oxy)phenethylcarbamate

Z-Phe-Phe^P-(OEt)(OTya-Boc) (11)



To the stirring solution of the amine H_2N -Phe^P-(OEt)(OTya-Boc) (**10**) (38 mg, 0.086 mmol, 1 eq.) in DCM (1 ml), Z-Phe-OH (62 mg, 0.103 mmol, 1.2 eq) was dissolved, followed by the addition of TBTU (78 mg, 0.206 mmol, 2.4 eq), HOBt (27 mg, 0.206 mmol, 2.4 eq.), and DIPEA (44 μ L, 0.258 mmol, 3 eq). The mixture was allowed to stir at rt, and DIPEA was added to maintain alkaline pH. When the DPP amine **10** was

consumed, the solution was concentrated, ethyl acetate (10 ml) was added, and the mixture was washed with H_2O (4 x 10 ml), 5% NaHCO₃ (3 x 10 ml), H_2O (10 ml), 10% citric acid (3 x 10 ml), H_2O (10 ml) and brine (10 ml). The organic phase was dried over Na₂SO₄, and the solvents were removed *in vacuo*. The crude product was purified in column chromatography (silica gel, hexane/ethyl acetate 80% to 60%) to give **11** as a white solid (30 mg, 47% after two steps).

 R_f : 0.54 (Hexane/EtOAc, 6:4).

¹**H-NMR** (600 MHz, CDCl₃) δ 7.35-7.06 (m, 19H), 6.98 (d, *J* = 3.4 Hz, 1H), 6.51-6.47 (m, 1H), 5.06-5.04 (m, 2H), 4.95-7.90 (m, 1H), 4.58-4.52 (m, 1H), 4.35-4.25 (m, 1H), (4.14-4.04 (m, 2H), 3.34-3.27 (m, 3H), 3.02-2.70 (m, 5H), 1.45 & 1.44 (s, 9H, isomers). ³¹**P-NMR** (243 MHz, CDCl₃) δ 20.36, 20.27, 20.22.

ESI-MS: m/z calcd for $[M+Na]^+ C_{40}H_{48}N_3NaO_8P^+$ 752.31, found 752.42; calcd for $[M+K]^+ C_{40}H_{48}KN_3O_8P^+$ 768.28, found 768.38.

Tert-butyl 4-(((1-(2-amino-3-phenylpropanamido)-2-phenylethyl)(ethoxy)phos-phoryl)oxy)phenethylcarbamate

H₂N-Phe-Phe^P-(OEt)(OTya-Boc) (12)



To the mixture of Z-Phe-Phe^P-(OEt)(OTya-Boc) (**11**) (20 mg, 27 μ mol, 1 eq.) and 10% Pd-C (4 mg, 20% w/w) in MeOH (0.5 ml), was added triethylsilane (44 μ L, 270 μ mol, 10 eq.) dropwise under nitrogen atmosphere. When the reaction was complete, the mixture was filtered through celite, and solvents evaporated *in vacuo*. The crude oil was used without further purification (16 mg crude).

 R_f : 0.08 (Hexane/EtOAc, 6:4).

ESI-MS: *m*/*z* calcd for [M+H]⁺C₃₂H₄₃N₃O₆P⁺ 596.29, found 596.37.

1-(6-((1-((1-((4-(2-((*tert*-butoxycarbonyl)amino)ethyl)phenoxy)(ethoxy) phosphoryl)-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-6oxohexyl)-3,3-dimethyl-2-((1*E*,3*E*,5*E*)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3*H*-indol-1-ium

Cy5-Phe-Phe^P-(OEt)(OTya-Boc) (13)



To a solution of **12** (8 mg, 13 μ mol, 1 eq.) in 150 μ L DMSO, a solution of Cy5-NHS (10 mg, 15.6 μ mol, 1.2 eq.) in 150 μ L DMSO was added, followed by the addition of DIPEA (11 μ L, 8.5 μ mol, 5 eq.). The reaction was monitored with HPLC till **12** was consumed. After 16 h, purification by HPLC (semi-preparatory reverse phase C₁₈ column,

CH₃CN/H₂O + 0.1% TFA, 25% for 3 min; 25% to 100% over 15 min, 1 ml/min) followed by lyophilization, afforded pure the TFA salt of product **13** as a blue powder (3.7 mg, yield 25% after two steps).

¹**H-NMR** (600 MHz, CDCl₃) δ 7.88 (d, *J* = 8.5 Hz, 1H), 7.44 (d, *J* = 8.3 Hz, 1H), 7.56 (t, *J* = 8.4 Hz, 1H), 7.49 (t, *J* = 8.4 Hz, 1H), 7.44-7.07 (m, 23H), 4.26-4.21 (m, 1H) 4.15-4.04 (m, 4H), 3.67-3.62 (m, 1H), 3.57-3.54 (m, 1H), 3.46 (s, 3H), 2.35 (t, *J* = 7.4 Hz, 6H), 2.26 (t, *J* = 6.0 Hz, 6H), 2.01 (d, *J* = 5.5 Hz, 2H), 1.71-1.59 (m, 6H), 1.40 (s, 9H), 1.14-1.19 (m, 3H). 6H peaks overlap with residual solvent peaks.

t_{*R*}: peak 1: 30.34 min (70.66% B), peak 2: 30.59 (71.15% B) (diasteromers); CH₃CN/H₂O + 0.1% TFA, 20% for 5 min; 20% to 100% over 40 min, 1 ml/min. **ESI-MS:** m/z calcd for [M]⁺ C₆₄H₇₉N₅O₇P⁺ 1060.57, found 1060.86; calcd for [M+Na]^{2+/2} C₆₄H₇₉N₅NaO₇P²⁺ 541.78, found 541.93. Both HPLC peaks gave the same ESI-MS.

1-(6-((1-((1-((4-(2-aminoethyl)phenoxy)(ethoxy)phosphoryl)-2phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-6-oxohexyl)-3,3dimethyl-2-((1*E*,3*E*,5*E*)-5-(1,3,3-trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3*H*-indol-1-ium

Cy5-Phe-Phe^P-(OEt)(OTya-NH₂) (14)

To a stirred solution of **13** (2 mg, 1.7 μ mol, 1 eq.) in DCM (0.1 ml), was added dropwise 0.1 ml TFA. After 2 h, the mixture was co-evaporated with toluene (3 x 0.3 ml) *in vacuo* on a rotavap to dryness. The crude amorphous TFA salt was used in the next reaction without further purification (2 mg crude).



t_{*R*}: peak 1: 23.08min (56.10% B), peak 2: 23.45 min (56.57% B) (diastereomers); CH₃CN/H₂O + 0.1% TFA, 20% for 5 min; 20% to 100% over 40 min, 1 ml/min.

ESI-MS: m/z calcd for $[M]^+$ C₅₉H₇₁N₅O₅P⁺ 960.52, found 960.72; calcd for $[(M+H)/2]^{2+}$ 480.76, found 480.91.

1-(6-((1-((1-(ethoxy(4-(2-(1-((2-((*E*)-3-(indolin-1-ium-1-ylidene)-6-(indolin-1-yl)-3*H*-xanthen-9-yl)phenyl)sulfonyl)piperidine-4carboxamido)ethyl)phenoxy)phosphoryl)-2-phenylethyl)amino)-1-oxo-3phenylpropan-2-yl)amino)-6-oxohexyl)-3,3-dimethyl-2-((1*E*,3*E*,5*E*)-5-(1,3,3trimethylindolin-2-ylidene)penta-1,3-dien-1-yl)-3*H*-indol-1-ium Cy5-Phe-Phe^P-(OEt)(OTya-QSY21) (15)



To a solution of 14 (2 mg, 1.7μ mol, 1 eq.) in DMSO (50 µL), a solution of QSY21-NHS (1.6 mg, 1.91 µmol, 1.1 eq.) in 50 µL DMSO was added, followed by the addition of DIPEA (1.5 µL, 8.5 µmol, 5 eq.). The reaction was monitored by RP-HPLC till 14 was consumed. After 16 h, purification by RP-HPLC (semi-preparative reverse phase C₁₈ column, CH₃CN/H₂O + 0.1% TFA, 25% for 3 min; 25% to 100% over 15 min, 1 ml/min) followed by lyophilization, afforded pure the TFA salt of product 15 as a dark blue powder (1.9 mg, yield 65% for

two reactions).

¹**H-NMR** (600 MHz, CDCl₃) δ 8.24-8.20 (m, 2H), 7.96-7.92 (m, 2H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.67-7.46 (m, 10H), 7.39-7.01 (m, 26H), 6.76 (d, *J* = 8.4 Hz, 1H), 4.34-4.07 (m, 9H), 3.75-3.73 (m, 2H), 3.57 (s, 3H) 3.19-3.18 (m, 2H), 2.58-2.53 (m, 6H), 2.36-2.06 (m, 6H), 2.05-1.98 (m, 2H), 1.85-1.69 (m, 8H), 1.65-1.45 (m, 6H), 1.24-1.23 (m, 3H). 10H peaks overlap with residual solvent peaks. **t**_{*R*}: peak 1: 29.30 min (69.48% B), peak 2: 30.18 min (69.95% B) (diastereomers); CH₃CN/H₂O + 0.1% TFA, 20% for 5 min; 20% to 100% over 40 min, 1 ml/min). **ESI-MS:** *m*/*z* calcd for [M]²⁺/2 C₁₀₀H₁₀₅N₈O₉PS²⁺ 812.87, found 812.96; calcd for [M+H]³⁺/3 542.25, found 542.33.

NMR, MS and HPLC raw data

¹H NMR (600 MHz, $CDCl_3$) of compound Z-Phe^P-(OPh)₂ (**4**).





³¹P NMR (243 MHz, $CDCl_3$) of compound Z-Phe^P-(OPh)₂ (**4**).

ESI-MS of compound Z-Phe^P-(OPh)₂ (**4**).



m/z calcd for [M+Na]⁺ C₂₈H₂₆NNaO₅P⁺ 510.14, found 510.27; calcd for [M+K]⁺ C₂₈H₂₆KNO₅P⁺ 526.12, found 526.22; calcd for [2M+Na]⁺ C₅₆H₅₂N₂NaO₁₀P₂⁺ 997.30, found 997.37.



¹³C NMR (151 MHz, $CDCl_3$) of compound Z-Phe^P-(OEt)₂ (**5**).

S88-B_13C





³¹P NMR (243 MHz, $CDCl_3$) of compound Z-Phe^P-(OEt)₂ (5).

ESI-MS of compound Z-Phe^P-(OEt)₂ (**5**).



¹H NMR (600 MHz, 298 K, CDCl₃) of compound Boc-NH-Tya-OH (**8**).

B44c5





S17



ESI-MS of compound Boc-NH-Tya-OH (8).

m/z calcd for [M+Na]⁺ C₁₃H₁₉NNaO₃⁺ 260.13, found 260.80.

¹H NMR (600 MHz, CDCl₃) of compound Z-Phe^P-(OEt)(OTya-Boc) (**9**).

B43IIc8-11



¹³C NMR (151 MHz, CDCl₃) of compound Z-Phe^P-(OEt)(OTya-Boc) (**9**).





B43IIc8-11 31P A 20.84 20.76 BRUK ER Current Data Parameters NAME B43IIc8-11_31P EXPNO 1 PROCNO 1 F2 - Acquisition Parameters Date_ 20191125 20.836 Time 11.39 h INSTRUM spect Z114607_0214 (PROBHD PULPROG zgpg30 65536 TD CDC13 $\backslash /$ SOLVENT NS 57 DS 4 SWH 96153.844 Hz FIDRES 2.934382 Hz 0.3407872 sec AQ RG 192.58 DW 5.200 usec DE TE 6.50 usec 298.2 K D1 2.00000000 sec D11 0.03000000 sec TD0 1 242.9249301 MHz SF01 NUC1 31P PO 4.00 usec P1 12.00 usec 36.85100174 W PLW1 SFO2 600.1324005 MHz -----NUC2 1H 21 20 ppm CPDPRG[2 waltz16 PCPD2 70.00 usec PLW2 27.59199905 W 0.56309998 W PLW12 PLW13 0.28323999 W F2 - Processing parameters SI 32768 SF 242.9370770 MHz WDW EM SSB 0 LB 1.00 Hz GB 0 PC 2.00

-100

-150

-200

ppm

-50

0

³¹P NMR (243 MHz, CDCl₃) of compound Z-Phe^P-(OEt)(OTya-Boc) (**9**).

100

50

S21

ESI-MS of compound Z-Phe^P-(OEt)(OTya-Boc) (9).



m/z calcd for [M+Na]⁺ C₃₁H₃₉N₂NaO₇P⁺ 605.24, found 605.30; calcd for [M+K]⁺ C₃₁H₃₉N₂KO₇P⁺ 621.21, found 621.23.

ESI-MS of crude compound H_2N -Phe^P-(OEt)(OTya-Boc) (**10**).



m/z calcd for [M+H]⁺ C₂₃H₃₄N₂O₅P⁺ 449.22, found 449.48.



¹H NMR (600 MHz, CDCl₃) of compound Z-Phe-Phe^P-(OEt)(OTya-Boc) (**11**).



³¹P NMR (243 MHz, CDCl₃)of compound Z-Phe-Phe^P-(OEt)(OTya-Boc) (**11**).

۳ ۳	S BI	RUKER
	- 20.	X
N N	Curre	nt Data Parameters
	NAME	E14c15-20_31P
	PROCN	0 1
	F2 - Date	Acquisition Parameters 20210114
	Time	16.43 h
	INSTR	UM spect
	PULPR	OG zapa30
	TD	65536
	SOLVE	NT CDC13
	NS	101
	SWH	96153.844 Hz
	FIDRE	S 2.934382 Hz
	AQ	0.3407872 sec
	RG	192.58
	DE	6.50 usec
	TE	298.2 K
	D1	2.00000000 sec
	D11	0.03000000 sec
	TDO	1 242 0240201 MU
	SF01 NUC1	242.9249301 MHz 31P
	PO	4.00 usec
	P1	12.00 usec
	PLW1	36.85100174 W
	SF02 NUC2	600.1324005 MHz
	CPDPR	G[2 waltz16
	PCPD2	70.00 usec
	PLW2	27.59199905 W
	PLW12	0.56309998 W
	PLW13	0.28323999 W
	F2 -	Processing parameters
	SI	32768 242 9370770 MHz
	5F WDW	242.9570770 MHZ EM
	SSB	0
	LB	1.00 Hz
	GB	0
	New York Control of the Control of t	2.00

55 50 45 40 35 30 25 20 15 10 5 0 -5 -10 -15 ppm

S25



ESI-MS of compound Z-Phe-Phe^P-(OEt)(OTya-Boc) (**11**).

m/z calcd for $[M+Na]^+ C_{40}H_{48}N_3NaO_8P^+$ 752.31, found 752.42; calcd for $[M+K]^+ C_{40}H_{48}KN_3O_8P^+$ 768.28, found 768.38.

ESI-MS of compound H₂N-Phe-Phe^P-(OEt)(OTya-Boc) (**12**).



618.36.



¹H NMR (600 MHz, CD₃OD) of compound Cy5-Phe-Phe^P-(OEt)(OTya-Boc) (**13**).



HPLC of compound Cy5-Phe-Phe^P-(OEt)(OTya-Boc) (**13**).







HPLC of compound Cy5-Phe-Phe^P-(OEt)(OTya-NH₂) (**14**).

t_R: peak 1: 23.08min (56.10% B); peak 2: 23.45 min (56.57% B) (diastereomers)



ESI-MS of compound Cy5-Phe-Phe^P-(OEt)(OTya-NH₂) (**14**).



¹H NMR (600 MHz, CD₃OD) of compound Cy5-Phe-Phe^P-(OEt)(OTya-QSY21) (**15**).

HPLC of compound Cy5-Phe-Phe^P-(OEt)(OTya-QSY21) (**15**).



t_{*R*}: peak 1: 29.30 min (69.48% B), peak 2: 30.18 min (69.95% B) (diastereomers).

ESI-MS of compound Cy5-Phe-Phe^P-(OEt)(OTya-QSY21) (**15**).



m/z calcd for $[M]^{2+}/2 C_{100}H_{105}N_8O_9PS^{2+}$ 812.87, found 812.96; calcd for $[M+H]^{3+}/3$ 542.25, found 542.33.